SVRA

Prior belief was that Savara's Molbreevi thesis required the BLA to remain under FDA review through the Nov. 22 PDUFA without a CRL. Since the last review, current searches found no cutoff-eligible CRL, safety issue, or regulatory withdrawal; the Aug. 11 update and Apr. 15 extension release confirm the PDUFA and extension rationale. The view is confirmed, with the binary FDA decision and launch financing still unresolved.

Previously we believed Savara's single-product thesis depended on Molbreevi staying under FDA review for the Nov. 22 PDUFA without a CRL. I found no eligible post-Aug. 24 CRL or safety/manufacturing setback; the Aug. 11 company update confirms the PDUFA date, EU and UK reviews, and launch cash, while the April 15 FDA-extension release says the extension cited no safety, efficacy, or manufacturing concerns. This repairs the evidence base and confirms the view, but FDA approval remains unresolved.

We previously believed Savara was a binary but de-risked regulatory long, with the Molbreevi BLA still under FDA review and the key invalidation trigger being a CRL by the Nov. 22 PDUFA date. This review found no cutoff-eligible post-review CRL, safety, efficacy, or manufacturing setback. The opened Savara Q2 update still lists the Nov. 22 PDUFA, EU and UK reviews, and launch-readiness cash, so the regulatory thesis remains alive. The unresolved issue is the FDA decision itself and whether approval arrives without label or financing surprises.

We previously believed Savara remained a binary Molbreevi regulatory idea with the Nov. 22 FDA PDUFA as the key trigger and a CRL as the kill switch. This run found no opened source reporting a CRL or new FDA concern; Savara’s current primary business update still lists the Nov. 22 PDUFA, EMA and MHRA reviews, and the cash position for launch readiness, while the earlier extension source still states no safety, efficacy or manufacturing concern was cited. The unresolved issue is still the FDA decision itself.

Nothing new since open: the molgramostim/Molbreevi BLA PDUFA remains Nov 22, 2026 under Priority Review, with the FDA still citing no safety, efficacy, or manufacturing concerns behind the earlier extension. Binary approval catalyst is intact and ahead; no CRL, no new data, so the invalidation trigger has not fired. Conviction unchanged.

PDUFA date of November 22, 2026 confirmed. FDA extended the review to allow evaluation of additional data — no safety, efficacy, or manufacturing concerns cited. New development since idea open: the EMA validated Molbreevi's Marketing Authorization Application with a Q1 2027 decision expected, adding a European approval pathway not reflected in the original thesis and increasing the total addressable market if both decisions go well. No adverse pipeline developments, no competitive approvals in aPAP. Stock down 1.3% since rec on no material change. Binary FDA binary decision remains the sole near-term catalyst; thesis intact and review on track.

Savara reported Q2 2026 financial results on August 11, 2026, showing ~$173M cash plus up to ~$150M non-dilutive capital contingent on approval — runway extends through the PDUFA. The November 22, 2026 FDA PDUFA date is on track; no new FDA signals of concern have emerged. An incremental positive: the EMA and UK MHRA are also reviewing molgramostim, with MHRA decisions expected Q4 2026 and EMA Q1 2027, confirming global first-in-disease positioning the thesis did not fully price. No CRL, no safety flag, no invalidation trigger.

No new developments since Aug 11 open. The Nov 22, 2026 PDUFA date and the FDA's stated absence of safety, efficacy, or manufacturing concerns were already incorporated in the thesis at open. Molgramostim BLA remains under Priority Review. No Complete Response Letter has been issued. Invalidation trigger has not fired. Binary catalyst unchanged.

No new adverse developments found since thesis opened Aug 11, 2026. The FDA extension of the review period to the Nov 22, 2026 PDUFA date was already fully captured in the thesis write-up; no Complete Response Letter issued and the FDA cited no safety, efficacy, or manufacturing concerns in its correspondence. Stock is essentially flat (-1.5%), within noise for a binary pre-PDUFA biotech. Thesis intact; the sole remaining catalyst is the Nov 22 binary approval decision for the first-ever aPAP therapy.

PDUFA date remains Nov 22, 2026 unchanged. The three-month clock extension was a major amendment (additional data submitted), with FDA citing zero safety, efficacy, or manufacturing concerns in its correspondence. IMPALA-2 was published in NEJM in August 2025. No adverse FDA feedback or competitive threats found. Binary first-in-disease approval event on track for Nov 22.

PDUFA target action date of November 22, 2026 confirmed. The FDA's three-month extension (from Aug 22 to Nov 22) was classified as a major amendment to review additional data submitted by Savara — the agency cited no safety, efficacy, or manufacturing concerns in its correspondence, consistent with the thesis framing. EMA also validated the Marketing Authorization Application for MOLBREEVI with a Q1 2027 European decision expected. No new adverse regulatory signals since the idea was opened Aug 11.

Opened by the biotech hunt.